Social media misinformation impacting menstrual health: Survey
The findings are part of the 10th annual edition of the everteen Menstrual Hygiene Survey, released ahead of Menstrual Hygiene Day.
New Delhi, May 27 (PTI) While a majority of Indian women consider social media a good source of information on menstruation, very few rely on it during menstrual emergencies, a recent survey said.
The survey states that while around 71.6 per cent of women believe that social media offers adequate information about menstruation, only 11.5 per cent rely on it as their primary source during menstrual emergencies.
'The fact that more than two-thirds of women in India are relying on social media as a source of information shows that influencers and bloggers are doing a fabulous job in creating awareness on menstrual hygiene,' Chirag Pan, CEO of PAN Healthcare, said.
'However, they have an even bigger responsibility in realising Prime Minister Narendra Modi's vision of a Viksit Bharat. It is imperative that the social media community builds viewer trust through accurate, fact-based and verified information,' he added.
Several women reported encountering misleading or harmful information online.
One recurring example was the false claim that delayed periods indicate Polycystic Ovarian Disease (PCOD). Others reported being advised to consume lemonade or coffee for period pain, which only worsened their symptoms.
Some respondents came across inaccurate home remedies, while others saw misinformation suggesting exercise during periods could harm the body — a notion that contradicts scientific evidence supporting light-to-moderate physical activity to relieve menstrual cramps and improve mood.
Hariom Tyagi, CEO of Wet and Dry Personal Care, the makers of everteen said the survey highlights a significant awareness gap.
'It is evident from our survey that while several women are searching, there is a lack of awareness on safe and effective solutions for menstrual cramps,' he said.
As many as 41.5 per cent of women reported not using any form of pain relief during menstruation, despite 82.7 per cent experiencing mild to severe pain.
Only 5.5 per cent were aware of the benefits of menstrual cramp roll-ons as an alternative to painkillers, which are used by 14.2 per cent of respondents, Tyagi said.
Women also noted the prevalence of social media content reinforcing menstrual taboos and myths — such as beliefs that menstrual blood is impure, that women should not visit religious places during periods, or that touching pickles or fermented foods can spoil them.
Other misleading claims included not washing hair during periods, avoiding white-coloured foods like milk and curd, and misconceptions such as light flow indicating infertility, or that women cannot get pregnant during menstruation.
Some posts falsely claimed that tampons could stretch intimate parts or instilled fear about using menstrual cups.
Another trend highlighted in the survey was the rising adoption of disposable period panties (5.7 per cent), which have overtaken menstrual cups (4.7 per cent) and tampons (1.6 per cent) in popularity. Sanitary pads remained the most widely used menstrual hygiene product, with 87.8 per cent of respondents preferring them.
The survey covered 1,152 women across India, including from Andhra Pradesh, Assam, Delhi, Gujarat, Haryana, Jammu and Kashmir, Karnataka, Kerala, Maharashtra, Manipur, Odisha, Punjab, Rajasthan, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal. PTI PLB MPL MPL
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
'Takes Skill To Be Still': Shubhanshu Shukla Shares Throwback Video Of Him Floating In Space
Shukla took to Instagram to share a video of his days at the space station, where he was seen trying to stay absolutely still in microgravity. Days after returning from a historic mission on the International Space Station, Indian Air Force pilot Group Captain Shubhanshu Shukla shared a video of his days at the space station, where he was seen trying to stay absolutely still in microgravity. Shukla, who was among the four crew members who flew aboard SpaceX Dragon on June 25, shared a video on Instagram of their first few days of the Axiom-4 mission, where he described the challenge of remaining immobile in space. 'From the time we reached ISS we were quite busy in chasing the timeline and completing our tasks and experiments. It is a bit challenging initially as you are learning to move in microgravity and also getting to know the station," he said in the caption. Shukla said the video was from a few days into the mission, when he had managed better control over his movements in space, while sitting in a cross-legged position. 'What I wanted to do was to be just still but clearly failed. Any small disturbance can move your body in space and it takes skill to be completely still," he said. 'Kind of like our minds in this fast moving world. Take some time to be still today. It is important to sometimes slow down to be fast. Apparently being still is a challenge with or without gravity," he added. Shukla returned safely to Earth as SpaceX's Dragon capsule, Grace, on July 15, after it made the splashdown into the Pacific Ocean, off the coast of San Diego in Southern California. ISRO confirmed that the initial health assessments indicated that Shukla was in stable condition and reported no immediate health concerns. He was flown to Houston, where he also met his family members, including his wife and child. He also met fellow Gaganyaan astronaut-designate Group Captain Prasanth Balakrishnan Nair, who trained alongside Shukla for the Axiom Mission-4 and remained on standby, and other ISRO team members. The space agency confirmed that Shukla has begun a week-long rehabilitation programme under the supervision of Axiom Space's flight surgeon and ISRO's flight surgeon to mitigate any adverse effects of microgravity. This includes a series of medical checks, especially cardiovascular assessments, musculoskeletal tests, and psychological debriefs. Launched on June 25, the mission marked the first time an Indian entered the International Space Station and performed experiments in microgravity. Shukla also brought along with him the results of the seven experiments, which were developed by Indian research institutions under the Human Space Flight Centre's coordination. First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
India.com
an hour ago
- India.com
Good news! Now you can get insurance for low price, get Rs 2 lakh cover for only Rs 20 in this govt scheme, name is….
Good news! Now you can get insurance for low price, get Rs 2 lakh cover for only Rs 20 in this govt scheme, name is…. Get Rs 2 lakh insurance for just a cost of two tea cups. Know about Pradhan Mantri Suraksha Bima Yojana here. By Joy Pillai Edited by Joy Pillai Advertisement Good news! Now you can get insurance for low price, get Rs 2 lakh cover for only Rs 20 in this govt scheme, name is.... Pradhan Mantri Suraksha Bima Yojana: Many people have a habit of drinking tea and smoking cigarettes. This habit affects health and, in the long run, causes serious diseases. But what if we tell you that you can buy insurance worth Rs 2 lakh just by skipping two cups of tea or a cigarette? Today, we are telling you about an insurance scheme that provides financial security at a very low premium. No, it is not a fraud scheme, and there are no hidden charges either, because the scheme is run by the Government of India. The name of this scheme is Pradhan Mantri Suraksha Bima Yojana (PMSBY). Let's know more about the scheme. What Is Pradhan Mantri Suraksha Bima Yojana? Pradhan Mantri Suraksha Bima Yojana is basically an accident insurance scheme which offers accidental death and disability cover on account of an accident. The aim of the scheme is to provide financial strength to economically weaker families. The premium under PMSBY is only Rs. 20 per year. Under this scheme, you can also deposit a premium of Rs. 2 every month. Under this scheme, this amount is deducted from your Aadhaar linked bank account every year. Advertisement === Key Features Of PMSBY If the insured person becomes completely disabled in an accident, then he is eligible to get Rs 2 lakh. In case of a partial accident, Rs 1 lakh is given under the scheme. Advertisement === The insurance can be renewed every year. If the policyholder dies, then this money is given to the family. Who Can Avail The Benefit? People between the ages of 18 to 70 can avail themselves of the benefits of the scheme. Notably, this policy ends automatically on completion of the age of 70 years. Only Indian citizens are eligible for the security insurance scheme. The applicant must have an active bank account in any bank, which is linked to Aadhaar. If your bank account is closed then this policy will also end. The policy cover period is between 1st June to 31st May. What Is The Process Of Applying? To apply for this insurance program, apply at your bank. The bank will provide an application form which, once completed and submitted with the required documents, will initiate the process.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
CDMOs gear up for peptide boom amid rising demand for weight-loss drugs
As global demand for next-generation weight-loss and diabetes therapeutics surges, India's contract development and manufacturing organisations (CDMOs) are strategically positioning themselves to capture a bigger share of the peptide market, particularly in anticipation of key patent expiries such as that of semaglutide—a blockbuster GLP-1 receptor agonist. India is poised to play a critical role in the global manufacturing of GLP-1 drugs, driven by soaring demand for therapies like semaglutide and tirzepatide. The GLP-1 market is projected to exceed $150 billion by 2030. India's peptide CDMO market, currently estimated at around $80 million, is expected to grow at a CAGR of 14 per cent until 2030. Though the country currently accounts for just 3 per cent of the global peptide CDMO space—valued at $190 billion—the growth momentum is unmistakable, according to Nilaya Varma, Co-founder and Group CEO of Primus Partners. Top Indian players in the space include Glenmark, Cipla, Divi's Laboratories, Themis Medicare, Peptomer Therapeutics, Syngene International, and Sai Life Sciences. Semaglutide patent expiry fuels strategic activity Semaglutide, the active ingredient in drugs such as Ozempic and Wegovy, is owned and produced by Novo Nordisk and is set to go off-patent in India in March 2026. Leading pharmaceutical companies, including Dr Reddy's Laboratories, Sun Pharma, Cipla, Mankind Pharma, Natco Pharma, Lupin, and Biocon, are preparing to launch drugs in this category. These companies are investing in R&D, manufacturing capacity, and collaborations to compete in this rapidly growing market. Anthem Biosciences is experiencing a surge in inquiries for peptide active pharmaceutical ingredients (APIs), including those related to weight loss. 'Semaglutide can be produced through total synthesis or biosynthetic routes. Very few companies in India can manage biosynthetic production—and we are one of them,' said Ganesh Sambasivam, Promoter and Chief Scientific Officer at Anthem. While he declined to confirm whether semaglutide is in active production at Anthem, he hinted that it may be among the peptides currently in development. Syngene highlights technical edge in peptide trials Jayashree Aiyar, Chief Scientific Officer at Syngene International, sees opportunities not just in manufacturing, but also in preclinical and clinical development. 'We've already supported preclinical studies on semaglutide and recently helped a global pharma company with a bioequivalence study using pre-filled pens,' Aiyar said. These studies included developing and validating sensitive LC-MS/MS methods to measure semaglutide plasma levels—a significant technical challenge for peptides. Syngene's case study on semaglutide demonstrates the rigorous planning and execution required for clinical bioequivalence trials involving peptides. With gastrointestinal side effects common among test subjects, the company had to implement robust risk management and continuous patient support mechanisms. On the analytical front, it overcame complex challenges like autosampler carryover and low detection limits through custom-developed chromatography and mass spectrometry protocols. 'While we are not currently manufacturing GLP-1 APIs, we are well-equipped with peptide scale-up and fill–finish capabilities. We continue to invest in technologies to meet future market needs,' Aiyar added. Production and compliance challenges persist However, peptide manufacturing comes with its own set of challenges. 'There are production hurdles involving the availability of protected amino acids, coupling reagents, and advanced purification protocols, particularly for bulk APIs,' Varma noted. These challenges, combined with high utility costs and stringent environmental controls, add pressure to meet international compliance standards. Schemes such as the 2024 Production Linked Incentive (PLI) and Greenfield Bulk Drug Park initiatives are expected to ease some of these bottlenecks. While some CDMOs are already entrenched in the space, others are evaluating the landscape. Kashmik Formulations, for instance, is not currently working on semaglutide or related APIs, nor has it received client inquiries. However, the company sees the patent expiry of semaglutide as a potential inflection point. 'We're open to collaborations with larger players who can provide validated processes,' the company said in a statement. Diabetes burden drives urgency for scalable solutions The spike in demand is closely linked to a global epidemic of lifestyle diseases. Arushi Jain, Director at Akums Drugs & Pharmaceuticals, underscores this urgency. 'Over 100 million Indians are living with diabetes, underlining the need for scalable therapeutic solutions that address root causes such as obesity.' Akums is actively tracking developments in weight-loss APIs. As patents for semaglutide and similar molecules expire, Indian CDMOs are gearing up for a new wave of growth. Equipped with scientific expertise, evolving infrastructure, and an appetite for collaboration, the Indian peptide manufacturing ecosystem is emerging as a vital player in the global fight against obesity and metabolic diseases.
